Insider Transactions in Q4 2024 at Solid Biosciences Inc. (SLDB)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 03
2024
|
Jessie Hanrahan Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
4,610
-24.46%
|
$23,050
$5.6 P/Share
|
|
Dec 03
2024
|
Alexander Cumbo President and CEO |
SELL
Open market or private sale
|
Direct |
11,114
-22.41%
|
$55,570
$5.6 P/Share
|
|
Dec 03
2024
|
David T Howton Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,072
-24.46%
|
$25,360
$5.6 P/Share
|
|
Dec 03
2024
|
Paul Herzich Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,777
-18.56%
|
$13,885
$5.6 P/Share
|
|
Dec 02
2024
|
Jessie Hanrahan Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,862
+38.63%
|
-
|
|
Dec 02
2024
|
Alexander Cumbo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,612
+36.58%
|
-
|
|
Dec 02
2024
|
David T Howton Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,051
+38.63%
|
-
|
|
Dec 02
2024
|
Paul Herzich Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,239
+32.61%
|
-
|
|
Oct 21
2024
|
Gabriel Brooks Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,923
-21.03%
|
$17,538
$6.5 P/Share
|
|
Oct 18
2024
|
Gabriel Brooks Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,750
+41.22%
|
-
|
|
Oct 03
2024
|
Ian F Smith |
BUY
Exercise of conversion of derivative security
|
Direct |
3,255
+2.88%
|
-
|